Three new bipartisan bills reframe the biotech workforce as a national security asset. Now it’s on employers to stop treating talent like a line item and start building the pipelines the industry actually runs on.
For more than a decade, I’ve watched the biotech industry struggle with its workforce strategy because most companies still treat hiring and talent development like a sunk cost. Hiring is something mostly still done reactively, and retention is something most companies don’t worry about after someone resigns. Meanwhile, every executive I talk to says the same thing: we can’t find the people we need, we’re losing decades of knowledge when someone on our staff retires or quits, and it’s burning our top people out because they have to work double, or correct other’s mistakes.
The truth is that most companies still don’t invest in their workforce pipeline.
This month, Congress took a swing at fixing that, and the framing matters as much as the legislation itself.
On May 20, the National Security Commission on Emerging Biotechnology (NSCEB) announced three bipartisan bills aimed squarely at the biotech talent pipeline: Representative Ro Khanna’s Federal Biotechnology Workforce Assessment Act, Representative Rich McCormick’s Biotechnology Workforce Alignment Act, and Representative Sarah McBride’s Biotechnology for All High School Students Act. Together, they direct the Office of Personnel Management to actually define what the federal biotech workforce is, push the National Science Foundation to align research funding with workforce pathways, and fund teacher training, lab equipment, and stackable biotech credentials in high schools across the country.
The headline from NSCEB Commissioner Paul Arcangeli should be tacked above every CHRO’s desk in this industry: “The biotechnology workforce is now a national security asset.” Not a cost center. Not a recruiting problem. An asset. The kind you fund, protect, and build for the long term.
That language is a significant shift. For years, the biotech workforce conversation has been dominated by quarterly headcount math, contract recruiter spend, and the eternal complaint that universities aren’t producing enough graduates. The NSCEB Action Plan reframes the problem: biotechnology is reshaping supply chains, reshoring manufacturing, securing food and energy production, and underwriting national defense. You don’t staff that with a job board and a prayer. You build infrastructure.
And critically, Arcangeli widened the lens beyond the PhD pipeline. The future biotech workforce, he said, has to include “life scientists, but also industrial technicians, mechanics, pipefitters, and other skilled workers who will power the biotechnology economy of the future.” Anyone who has set foot on a CDMO floor knows this is the truth no one writes grants about. The bottleneck isn’t always the scientist. It’s the QC tech, the process engineer, the validation specialist, the automation technician. Now with Biopharma committing billions of dollars of capital projects to the US, the bottleneck is quickly becoming those in the skilled trades who understand biotech.
This is something that Heffron Company thinks about every day. As a 104 year old mechanical contractor who specializes in biopharma and has helped to build some of the most advanced facilities in the MidAtlantic, they have earned the trust of the top biopharma companies but they know that it all boils down to their people.
This isn’t just a hiring problem. It’s a competitiveness problem.
To understand why Congress is moving on workforce now, you have to read the NSCEB final report and Action Plan from April 2025. The Commission’s conclusion was, in its own word, “sobering”: the United States has roughly a three-year window to act on biotechnology, or risk ceding the lead to China in a setback the report warns we “may never recover” from.
That isn’t hyperbole from a think tank. NSCEB is a bipartisan, Congressionally-chartered commission with members from both chambers and senior leaders from industry, academia, and the national security community. When that group says the window is closing, Washington listens, and as of January 2026, Congress had already taken legislative action on 32 NSCEB-aligned provisions, with 21 signed into law.
The picture has only gotten worse since. In December 2025, NSCEB published a follow-on assessment of the U.S.-China biotechnology competition that found China is now beginning to outpace the United States in certain domains of biopharmaceutical innovation. The Commission’s framing: China has spent two decades building a vertically integrated biotech ecosystem with a “whole-of-nation approach,” and without swift policy action, jobs, research, and industry growth will continue to migrate there. That’s not a 2040 problem. That’s happening now.
Here’s the part of the report that should land hardest with executives in this region: China didn’t build that ecosystem by luck. They built it by treating biotechnology as national infrastructure, with twenty years of coordinated investment in capacity, capital, and people. The U.S. has the science, the capital markets, the regulatory framework, and the entrepreneurial culture to compete. What we don’t have, and what we are running out of time to build, is the workforce.
If we lose this race, we don’t lose it because Chinese scientists outsmart American scientists. We lose it because we couldn’t staff the facilities, fill the manufacturing reqs, or keep institutional knowledge from walking out the door every time a senior tech retired. The Commission says it directly: America’s biotech leadership will ultimately depend on people as much as technology. Federal policy can do part of the work. The rest has to come from industry.
This is the moment for U.S. employers to step up. Not because it polls well. Because if we don’t, the bioeconomy we spent half a century building gets handed to a competitor who has been quietly working the long game while we optimized quarterly hiring metrics.
Federal policy is necessary. It’s not sufficient.
Here’s the part employers need to hear clearly: these bills, even passed and fully funded, will take years to move the needle. OPM assessments, NSF grant cycles, and high school curriculum rollouts operate on timelines that don’t match the hiring crisis on your manufacturing floor next quarter. Federal policy sets the conditions. It doesn’t fill your reqs.
That’s the gap BioBuzz has spent the last decade building infrastructure to close, and it’s why we launched the BioCatalyst Workforce Program, funded in part by TEDCO, earlier this year. BioCatalyst is the operationalization of everything Congress is now codifying at the federal level: regional talent pipelines tied to real industry demand, training tracks built around what employers actually hire for, and a community layer that keeps people in the industry instead of losing them to adjacent sectors after eighteen months.
The approach that we have formulated over the past two decades is what we call “Talent Logistics.” The name itself implies our deep rooted philosophy on talent as infrastructure, as further articulated in an article by Outsourced Pharma — “Talent Logistics Turns Biotech Winter To Hiring Spring.”
Our mission at BioBuzz is to scale our workforce infrastructure platform nationally through a national network of connected biotech hubs.
The call to action for employers
If you run a life sciences company in this region, here’s the honest assessment: you are competing for talent against companies that have already started treating workforce as infrastructure. They are building employer brand year-round, not just when they have an open req. They are investing in apprenticeships, internships, and entry-level pipelines that pay off in eighteen to thirty-six months. They are showing up at community events, partnering with training programs, and building relationships with talent before they need to hire.
You’re also competing with China and now, more than ever, you need to have the right talent and human capital working for you to better innovate and produce in today’s market.
The strategic shift is simple to describe and uncomfortable to execute: stop treating talent as a cost center and start treating it as infrastructure. Infrastructure gets capex. Infrastructure gets multi-year budgets. Infrastructure gets executive sponsorship. Infrastructure gets built before you need it, not after the line goes down.
Congress is finally catching up to what those of us in the trenches have been saying for years. The companies that get ahead of this, that partner with programs like BioCatalyst now, that build their pipelines before the federal policy machinery delivers its first cohort of credentialed high school graduates in 2030, are the ones who will still be standing when the bioindustrial revolution that NSCEB keeps talking about actually arrives.
To learn more about partnering with the BioCatalyst Workforce Program as an employer, visit BioBuzz Networks or reach out to our team directly.
